COVID-19: Clouds Over the Antimicrobial Resistance Landscape

Arch Med Res. 2021 Jan;52(1):123-126. doi: 10.1016/j.arcmed.2020.10.010. Epub 2020 Oct 10.

Abstract

In recent years, the increase in antimicrobial resistance (AMR) has been recognized as a real threat to human and animal health. It is a problem that has been given the highest priority, uniting nations in the fight against its causes and effects. Among the actions that have been implemented are: clinical and microbiological surveillance, promotion of rational and controlled use of antibiotics, AMR stewardship programs in hospitals, development of tools for rapid diagnosis of infectious diseases to establish prompt and adequate treatment, and radically improving vaccination strategies. The current COVID-19 pandemic has placed disproportionate demands on the healthcare infrastructure and economy worldwide, which will negatively impact on the availability of materials as well as the technical capacity for diagnosis, patient care, and treatment of both COVID-19 and non-COVID-19 patients. Disruptions to production and distribution chains will hamper the availability and usage of antibiotics, also interrupting several of the activities that have been implemented thus far to combat AMR, including detailed laboratory monitoring and reinforced vaccination programs. Here, we discuss the main aspects that should be considered with regard to AMR, that may be affected by the pandemic and propose some actions to counter them.

Keywords: Anti-bacterial agents; Antimicrobial stewardship; Coronavirus pandemic; Drug resistance; Microbial.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • COVID-19 / epidemiology*
  • COVID-19 / microbiology
  • COVID-19 Drug Treatment*
  • Drug Resistance, Bacterial*
  • Humans
  • Pandemics
  • SARS-CoV-2 / isolation & purification

Substances

  • Anti-Bacterial Agents